Trajectory of immune evasion and cancer progression in hepatocellular carcinoma

肝细胞癌免疫逃逸和癌症进展的轨迹

阅读:6
作者:Phuong H D Nguyen # ,Martin Wasser # ,Chong Teik Tan ,Chun Jye Lim ,Hannah L H Lai ,Justine Jia Wen Seow ,Ramanuj DasGupta ,Cheryl Z J Phua ,Siming Ma ,Jicheng Yang ,Sheena D/O Suthen ,Wai Leong Tam ,Tony K H Lim ,Joe Yeong ,Wei Qiang Leow ,Yin Huei Pang ,Gwyneth Soon ,Tracy Jiezhen Loh ,Wei Keat Wan ,Chung Yip Chan ,Peng Chung Cheow ,Han Chong Toh ,Alfred Kow ,Yock Young Dan ,Juinn Huar Kam ,Shridhar Iyer ,Krishnakumar Madhavan ,Alexander Chung ,Glenn K Bonney ,Brian K P Goh ,Naiyang Fu ,Victor C Yu ,Weiwei Zhai ,Salvatore Albani ,Pierce K H Chow ,Valerie Chew

Abstract

Immune evasion is key to cancer initiation and later at metastasis, but its dynamics at intermediate stages, where potential therapeutic interventions could be applied, is undefined. Here we show, using multi-dimensional analyses of resected tumours, their adjacent non-tumour tissues and peripheral blood, that extensive immune remodelling takes place in patients with stage I to III hepatocellular carcinoma (HCC). We demonstrate the depletion of anti-tumoural immune subsets and accumulation of immunosuppressive or exhausted subsets along with reduced tumour infiltration of CD8 T cells peaking at stage II tumours. Corresponding transcriptomic modification occur in the genes related to antigen presentation, immune responses, and chemotaxis. The progressive immune evasion is validated in a murine model of HCC. Our results show evidence of ongoing tumour-immune co-evolution during HCC progression and offer insights into potential interventions to reverse, prevent or limit the progression of the disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。